Advertisement

 

 

Belatacept conversion in an HIV-positive kidney transplant recipient following anti-thymocyte globulin induction.

Belatacept conversion in an HIV-positive kidney transplant recipient following anti-thymocyte globulin induction.
Author Information (click to view)

Kuten SA, Patel SJ, Baru A, Gaber AO, Crutchley RD, Ramanathan V, Knight RJ,


Kuten SA, Patel SJ, Baru A, Gaber AO, Crutchley RD, Ramanathan V, Knight RJ, (click to view)

Kuten SA, Patel SJ, Baru A, Gaber AO, Crutchley RD, Ramanathan V, Knight RJ,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Transplant infectious disease : an official journal of the Transplantation Society 2017 07 14() doi 10.1111/tid.12748

Abstract

Herein, we describe a case of early belatacept conversion in a human immunodeficiency virus (HIV)-positive kidney transplant recipient in an effort to improve suboptimal graft function and avoid drug interactions following anti-thymocyte globulin (ATG) administration. We observed improvement in renal function without HIV disease progression or opportunistic infections. Donor-specific antibodies appeared shortly after conversion but cleared without intervention. This case highlights belatacept as a means to improve renal function and avoid significant drug interactions even following ATG induction. This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

14 − three =

[ HIDE/SHOW ]